• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Redmile Group, Llc was granted 14,808,234 shares (Amendment)

    10/18/21 4:06:23 PM ET
    $LSAQ
    Business Services
    Finance
    Get the next $LSAQ alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Redmile Group, LLC

    (Last) (First) (Middle)
    ONE LETTERMAN DRIVE, BUILDING D
    SUITE D3-300

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Science 37 Holdings, Inc. [ SNCE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/06/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    10/08/2021
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock(2) 10/06/2021 A 14,808,234(1)(2)(3) A (2) 19,808,234 I See footnote(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Redmile Group, LLC

    (Last) (First) (Middle)
    ONE LETTERMAN DRIVE, BUILDING D
    SUITE D3-300

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Green Jeremy

    (Last) (First) (Middle)
    C/O REDMILE GROUP, LLC
    ONE LETTERMAN DRIVE, BLDG D SUITE D3-300

    (Street)
    SAN FRANCISCO CA 94129

    (City) (State) (Zip)
    Explanation of Responses:
    1. On October 8, 2021, the Reporting Persons filed a Form 4 that inadvertently misstated the amount of securities acquired and beneficially owned. This amendment reports the shares of the Issuer's Common Stock issued to the Redmile Funds based on the corrected exchange ratio listed in footnote (3) below.
    2. On October 6, 2021, pursuant to the agreement and plan of merger, dated May 6, 2021 (the "Merger Agreement"), LifeSci Acqisition II Corp. ("LSAQ" or "Issuer"), LifeSci Acquisition II Merger Sub, Inc. ("Merger Sub") and Science 37, Inc. ("Science 37") consummated a business combination (the "Business Combination"), in which Merger Sub merged with and into Science 37 with Science 37 surviving the merger as a wholly-owned subsidiary of LSAQ (which subsequently changed its name to "Science 37 Holdings, Inc.").
    3. Pursuant to the terms of the Merger Agreement, the investors in Science 37 ("Legacy Investors") at the effective time of the Merger received approximately 1.815 shares of Issuer's Common Stock for each share of common stock of Science 37 held by them immediately prior to the effective time and a contingent right to additional shares of Issuer's Common Stock as described in Note 3 below, subject to the terms of the Merger Agreement. The Legacy Investors included certain private investment vehicles managed by Redmile Group, LLC (each, a "Redmile Fund").
    4. These securities are directly owned by the Redmile Funds and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (collectively, the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Reporting Persons are a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    Remarks:
    Robert Faulkner, a member of the board of directors of the Issuer and a managing director of Redmile, was appointed to the board of the Issuer as a representative of Redmile. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.
    By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC 10/18/2021
    /s/ Jeremy Green 10/18/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LSAQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LSAQ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LSAQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Science 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE

    Science 37 to debut on Nasdaq as a publicly traded company under ticker symbol "SNCE"Business combination will provide Science 37 with approximately $235 million in cash proceeds to support continued growthScience 37 to fuel its mission to enable universal access to clinical research which has proven to accelerate patient enrollment, minimize patient burden, and include underserved patient populations Investments targeted to enhance the Science 37 Operating System to decentralize clinical trial execution and enable more agile clinical trials LOS ANGELES and NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Science 37, Inc., the Operating System for today's agile clinical trials, announced today

    10/7/21 8:00:00 AM ET
    $LSAQ
    Business Services
    Finance

    LifeSci Acquisition II Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination

    NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ:LSAQ), a blank check company formed for the purpose of pursuing targets that are focused on healthcare innovation, today announced the confidential submission with the U.S. Securities and Exchange Commission ("SEC") of a draft registration statement on Form S-4 (the "Registration Statement") relating to its previously announced proposed business combination with Science 37, Inc. About LifeSci Acquisition II Corp. LifeSci Acquisition II Corp. (NASDAQ:LSAQ) is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganizat

    6/16/21 9:00:00 AM ET
    $LSAQ
    Business Services
    Finance

    Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operating System of the Future

    Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and power the next generation in clinical research $80 million via LifeSci Acquisition II Corp., a special purpose acquisition company with no public warrants $200 million via fully committed and upsized PIPE from leading institutional and strategic investors including Redmile Group; funds and accounts managed by BlackRock; Casdin Capital; dRx Capital (Novartis Pharma AG); LifeSci Venture Partners; Lux Capital; Mubadala Capital, the asset manageme

    5/7/21 7:55:00 AM ET
    $LSAQ
    Business Services
    Finance

    $LSAQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider De Silva Bhooshitha B.

    3 - Science 37 Holdings, Inc. (0001819113) (Issuer)

    10/18/21 4:48:37 PM ET
    $LSAQ
    Business Services
    Finance

    SEC Form 3: New insider Pharmaceutical Product Development, Llc claimed ownership of 17,314,315 shares

    3 - Science 37 Holdings, Inc. (0001819113) (Issuer)

    10/18/21 4:46:17 PM ET
    $LSAQ
    Business Services
    Finance

    SEC Form 3: New insider Lux Capital Management, Llc claimed ownership of 15,164,556 shares

    3 - Science 37 Holdings, Inc. (0001819113) (Issuer)

    10/18/21 4:32:23 PM ET
    $LSAQ
    Business Services
    Finance

    $LSAQ
    SEC Filings

    View All

    LifeSci Acquisition II Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    8-K - Science 37 Holdings, Inc. (0001819113) (Filer)

    10/13/21 5:26:13 PM ET
    $LSAQ
    Business Services
    Finance

    LifeSci Acquisition II Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure

    8-K - Lifesci Acquisition II Corp. (0001819113) (Filer)

    10/6/21 4:47:03 PM ET
    $LSAQ
    Business Services
    Finance

    SEC Form 424B3 filed by LifeSci Acquisition II Corp.

    424B3 - Lifesci Acquisition II Corp. (0001819113) (Filer)

    9/24/21 7:01:10 AM ET
    $LSAQ
    Business Services
    Finance

    $LSAQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by LifeSci Acquisition II Corp.

    SC 13D - Science 37 Holdings, Inc. (0001819113) (Subject)

    10/18/21 4:30:20 PM ET
    $LSAQ
    Business Services
    Finance

    SEC Form SC 13D filed by LifeSci Acquisition II Corp.

    SC 13D - Science 37 Holdings, Inc. (0001819113) (Subject)

    10/18/21 4:16:02 PM ET
    $LSAQ
    Business Services
    Finance

    SEC Form SC 13D filed by LifeSci Acquisition II Corp.

    SC 13D - Science 37 Holdings, Inc. (0001819113) (Subject)

    10/18/21 4:05:14 PM ET
    $LSAQ
    Business Services
    Finance